Tag:
Virtual model
Latest Headlines
Latest Headlines
Astellas, biotech VCs to pump $14M into virtual drug developer
Astellas and venture firms Interwest Partners and Sutter Hill Ventures plan to invest $14 million into a startup called Telsar Pharma.
Growing popularity of virtual biotechs promises boon to outsourcers
The recent news that tiny FerroKin BioSciences earned a big buyout deal with Shire has helped spotlight the growing virtual biotech model.
Growing popularity of virtual biotechs promises boon to outsourcers
News that tiny FerroKin BioSciences earned a big buyout deal with Shire ($SHPGY) has helped spotlight the growing popularity of the virtual biotech model.
Virtual is beautiful in biotech
I had the chance to moderate a panel at the BIO-Europe Spring meeting yesterday on new business models in biotech, with Torbjorn Bjerke, David Collier, Kevin Johnson, and Thomas Zioncheck joining the conversation.
Dennis Goldberg's neXus is a one-man biotech operation
Dennis Goldberg runs the ultimate virtual biotech company. He is the CEO of neXus therapeutics, which he runs alone out of his living room and funds through his Schwab account. All of the research
Can "backyard biotechs" beat Big Pharma at the development game?
Over the last few years, the virtual biotech model has become one of the hottest topics on the industry's bustling circuit of partnering and association gatherings. Every drug developer is being
The virtual model works for biotech, Big Pharma
The virtual model of drug development features a core management group that coordinates R&D activities, which are largely outsourced to other parties. The benefits include less overhead and
